Literature DB >> 16258856

Citicoline inhibits MAP kinase signalling pathways after focal cerebral ischaemia.

J Krupinski1, M Slevin, L Badimon.   

Abstract

The link between membrane phospholipids and different intracellular signal transduction pathways affected by cerebral ischaemia is unclear. CDP-choline, a major neuronal membrane lipid precursor and its intracellular target proteins and transcription factors were studied to further understand its role in ischaemic stroke. Cerebral ischaemia was produced by distal, permanent occlusion of the middle cerebral artery (MCAO) in the rat. Animals receiving 500 mg/kg of CDP-choline in 0.5 ml of 0.9% saline, intraperitoneally, 24 h and 1 h before MCAO and 23 h after MCAO demonstrated a notable reduction in the phosphorylation of MAP-kinase family members, ERK1/2 and MEK1/2, as well as Elk-1 transcription factor, compared with control animals treated with 0.5 ml of 0.9% saline. Immunohistochemistry showed a particular reduction in immunoreactivity in glia. The effects of CDP-choline on intracellular mechanisms of signal transduction, suggests that this molecule may play a key role in recovery after ischaemic stroke.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16258856     DOI: 10.1007/s11064-005-7201-0

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  30 in total

1.  Activation of p38MAPK in microglia after ischemia.

Authors:  K M Walton; R DiRocco; B A Bartlett; E Koury; V R Marcy; B Jarvis; E M Schaefer; R V Bhat
Journal:  J Neurochem       Date:  1998-04       Impact factor: 5.372

Review 2.  Protein kinase cascades activated by stress and inflammatory cytokines.

Authors:  J M Kyriakis; J Avruch
Journal:  Bioessays       Date:  1996-07       Impact factor: 4.345

Review 3.  Transducing signals of life and death.

Authors:  J Yuan
Journal:  Curr Opin Cell Biol       Date:  1997-04       Impact factor: 8.382

Review 4.  Mitogen-activated protein kinase pathways.

Authors:  M J Robinson; M H Cobb
Journal:  Curr Opin Cell Biol       Date:  1997-04       Impact factor: 8.382

5.  A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group.

Authors:  W M Clark; S J Warach; L C Pettigrew; R E Gammans; L A Sabounjian
Journal:  Neurology       Date:  1997-09       Impact factor: 9.910

6.  Neuroprotective agent chlomethiazole attenuates c-fos, c-jun, and AP-1 activation through inhibition of p38 MAP kinase.

Authors:  A Simi; M Ingelman-Sundberg; N Tindberg
Journal:  J Cereb Blood Flow Metab       Date:  2000-07       Impact factor: 6.200

Review 7.  Neuronal protein kinase signaling cascades and excitotoxic cell death.

Authors:  S D Skaper; L Facci; P J Strijbos
Journal:  Ann N Y Acad Sci       Date:  2001-06       Impact factor: 5.691

8.  Regional selective neuronal degeneration after protein phosphatase inhibition in hippocampal slice cultures: evidence for a MAP kinase-dependent mechanism.

Authors:  E Rundén; P O Seglen; F M Haug; O P Ottersen; T Wieloch; M Shamloo; J H Laake
Journal:  J Neurosci       Date:  1998-09-15       Impact factor: 6.167

9.  Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport.

Authors:  Olivia Hurtado; María A Moro; Antonio Cárdenas; Verónica Sánchez; Paz Fernández-Tomé; Juan C Leza; Pedro Lorenzo; Julio J Secades; Rafael Lozano; Antoni Dávalos; José Castillo; Ignacio Lizasoain
Journal:  Neurobiol Dis       Date:  2005-03       Impact factor: 5.996

Review 10.  Citicoline mechanisms and clinical efficacy in cerebral ischemia.

Authors:  Rao Muralikrishna Adibhatla; J F Hatcher
Journal:  J Neurosci Res       Date:  2002-10-15       Impact factor: 4.164

View more
  7 in total

1.  Monosialotetrahexosy-1 ganglioside attenuates diabetes-enhanced brain damage after transient forebrain ischemia and suppresses phosphorylation of ERK1/2 in the rat brain.

Authors:  Jian-Zhong Zhang; Li Jing; Yi Ma; Feng-Ying Guo; Yue Chang; P Andy Li
Journal:  Brain Res       Date:  2010-06-08       Impact factor: 3.252

Review 2.  Small molecule inhibitors in the treatment of cerebral ischemia.

Authors:  Jerry J Flores; Yang Zhang; Damon W Klebe; Tim Lekic; Weiling Fu; John H Zhang
Journal:  Expert Opin Pharmacother       Date:  2014-02-04       Impact factor: 3.889

3.  Oxidized low-density lipoprotein-induced matrix metalloproteinase-9 expression via PKC-delta/p42/p44 MAPK/Elk-1 cascade in brain astrocytes.

Authors:  Hui-Hsin Wang; Hsi-Lung Hsieh; Cheng-Ying Wu; Chuen-Mao Yang
Journal:  Neurotox Res       Date:  2009-06-25       Impact factor: 3.911

Review 4.  Neuroprotective properties of citicoline: facts, doubts and unresolved issues.

Authors:  Pawel Grieb
Journal:  CNS Drugs       Date:  2014-03       Impact factor: 5.749

Review 5.  Personalizing the Care and Treatment of Alzheimer's Disease: An Overview.

Authors:  Dubravka Svob Strac; Marcela Konjevod; Marina Sagud; Matea Nikolac Perkovic; Gordana Nedic Erjavec; Barbara Vuic; Goran Simic; Vana Vukic; Ninoslav Mimica; Nela Pivac
Journal:  Pharmgenomics Pers Med       Date:  2021-05-28

Review 6.  The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives.

Authors:  Pietro Gareri; Alberto Castagna; Antonino Maria Cotroneo; Salvatore Putignano; Giovambattista De Sarro; Amalia Cecilia Bruni
Journal:  Clin Interv Aging       Date:  2015-09-03       Impact factor: 4.458

Review 7.  Citicoline in Ophthalmological Neurodegenerative Disease: A Comprehensive Review.

Authors:  Francesco Oddone; Luca Rossetti; Mariacristina Parravano; Diego Sbardella; Massimo Coletta; Lucia Ziccardi; Gloria Roberti; Carmela Carnevale; Dario Romano; Gianluca Manni; Vincenzo Parisi
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.